From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Proteinkinase G inhibitor-1 (Compound 270) is a mycobacterial proteinkinase Ginhibitor, with an IC50 of 0.9 μM. Proteinkinase G inhibitor-1 can be used for mycobacterial infection research .
HA-100 is a potent proteinkinaseinhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent proteinkinase (PKG), cAMP-dependent proteinkinase (PKA), proteinkinase C (PKC) and MLC-kinase, respectively. HA-100 also used as a ROCKinhibitor .
Proteinkinase D inhibitor 1 (compound 17m) is a pan-PKDinhibitor, with IC50 values ranging from 17 to 35 nM. Proteinkinase D inhibitor 1inhibits PKD-dependent cortactin phosphorylation .
HA-100 hydrochloride is a potent proteinkinaseinhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent proteinkinase (PKG), cAMP-dependent proteinkinase (PKA), proteinkinase C (PKC) and MLC-kinase, respectively. HA-100 hydrochloride also used as a ROCKinhibitor .
HA-100 dihydrochloride is a potent proteinkinaseinhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent proteinkinase (PKG), cAMP-dependent proteinkinase (PKA), proteinkinase C (PKC) and MLC-kinase, respectively. HA-100 dihydrochloride also used as a ROCKinhibitor .
Risvodetinib is a potent protein tyrosine kinaseinhibitor. Risvodetinib involves in synthesis of Abelson proteinkinases (c-Abl1, c-Abl2, and c-kit) inhibitor .
RIP2 kinaseinhibitor 1 (compound 11) is a potent and selective receptor interacting protein 2 (RIP2)kinaseinhibitor with an IC50 of 0.03 μM for RIP2 FP. RIP2 kinaseinhibitor 1 is used for autoinflammatory disorders .
PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent proteinkinase), with a Ki of 2.3 nM. PKI(5-24) corresponds to residues 5-24 in the naturally occurring heat-stable proteinkinaseinhibitor .
Pim-1/2 kinaseinhibitor 1 is an orally active pim-1/2 kinaseinhibitor. Pim-1/2 kinaseinhibitor 1 blocks the ability of Pim kinases to phosphorylate peptides, and inhibits the pim proteinkinase directed phosphorylation of 4E-BP1 and p27 Kip1. Pim-1/2 kinaseinhibitor 1 can be used in study of cancer, especially prostate cancer .
PKI(5-24) TFA is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent proteinkinase), with a Ki of 2.3 nM. PKI(5-24) TFA corresponds to residues 5-24 in the naturally occurring heat-stable proteinkinaseinhibitor .
TAK1/MAP4K2 inhibitor 1 is a potent dual TGFβ-activated kinase 1 (TAK1) and mitogen-activated proteinkinasekinasekinasekinase 2 (MAP4K2) inhibitor, with IC50s of 41.1 nM and 18.2 nM, respectively.
EML4-ALK kinaseinhibitor 1 is a potent orally active inhibitor of echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase(EML4-ALK), with an IC50 of 1 nM .
Vibsanin A, a proteinkinase C (PKC) activator, exhibits anti-proliferative activity against human cancer cell lines. Vibsanin A is also a HSP90inhibitor .
FIM-1 is a fluorescent PKC (proteinkinase C) probe that can be used for mitochondrial staining. FIM-1 inhibits PKC and acts as ATP-competitive catalytic site inhibitor .
Poloppin is a potent, cell penetrant inhibitor of the mitotic Polo-like kinase (PLK) (IC50=26.9 μM) and prevents the protein-protein interaction via the Polo-box domain (PBD) (Kd= 29.5 μM). Poloppin selectively kills cells expressing mutant KRAS, enhancing death in mitosis. Poloppin is used for the study of KRAS-mutant cancers as single agents, or in combination with c-MET inhibitors .
Ilaprazole (IY-81149) sodium is an orally active proton pumpinhibitor. Ilaprazole sodium irreversibly inhibitsH +/K +-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium is used for the research of gastric ulcers. Ilaprazole sodium is also a potent TOPK (T-lymphokine-activated killer cell-originated proteinkinase) inhibitor .
Ilaprazole (IY-81149) sodium hydrate is an orally active proton pumpinhibitor. Ilaprazole sodium hydrate irreversibly inhibitsH +/K +-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium hydrate is used for the research of gastric ulcers. Ilaprazole sodium hydrate is also a potent TOPK (T-lymphokine-activated killer cell-originated proteinkinase) inhibitor .
Ilaprazole (IY-81149) is an orally active proton pumpinhibitor. Ilaprazole irreversibly inhibitsH +/K +-ATPase in a dose-dependent manner with an IC50 of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Ilaprazole is used for the research of gastric ulcers. Ilaprazole is also a potent TOPK (T-lymphokine-activated killer cell-originated proteinkinase) inhibitor .
Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a Srcinhibitor .
Beclin1-ATG14L interaction inhibitor 1 (com 19) is a selective Beclin1-ATG14L interaction inhibitor. This protein interaction mechanism specifically targets complex I of the lipid kinase VPS34 without affecting complex II. Because the integrity of VPS34 complex II depends on the Beclin 1-UVRAG interaction. Beclin1-ATG14L interaction inhibitor 1 can disrupt the formation of VPS34 complex I and inhibit autophagy, but does not affect complex II-related vesicle transport .
FIM-1 is a fluorescent PKC (proteinkinase C) probe that can be used for mitochondrial staining. FIM-1 inhibits PKC and acts as ATP-competitive catalytic site inhibitor .
PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent proteinkinase), with a Ki of 2.3 nM. PKI(5-24) corresponds to residues 5-24 in the naturally occurring heat-stable proteinkinaseinhibitor .
Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a Srcinhibitor .
PKI(5-24) TFA is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent proteinkinase), with a Ki of 2.3 nM. PKI(5-24) TFA corresponds to residues 5-24 in the naturally occurring heat-stable proteinkinaseinhibitor .
Vibsanin A, a proteinkinase C (PKC) activator, exhibits anti-proliferative activity against human cancer cell lines. Vibsanin A is also a HSP90inhibitor .
PKCi protein has adenosine 5'-monophosphate amidase activity and can hydrolyze compounds such as AMP-NH2. It also acts on AMP-morpholidate, GMP-morpholidate, lysyl-AMP, Met-AMP, His-AMP, Asp-AMP, lysyl-GMP and AMP-N-alanine methyl ester. PKCi Protein, Human is the recombinant human-derived PKCi protein, expressed by E. coli , with tag free. The total length of PKCi Protein, Human is 126 a.a., .
PKCi protein has adenosine 5'-monophosphate amidase activity and can hydrolyze compounds such as AMP-NH2. It also acts on AMP-morpholidate, GMP-morpholidate, lysyl-AMP, Met-AMP, His-AMP, Asp-AMP, lysyl-GMP and AMP-N-alanine methyl ester. PKCi Protein, Human (His) is the recombinant human-derived PKCi protein, expressed by E. coli , with N-6*His labeled tag. The total length of PKCi Protein, Human (His) is 126 a.a., .
The CDKN1B protein is a key cell cycle regulator that inhibits CDK2 when bound to cyclin A, thereby inhibiting G1 phase progression. It exhibits significant inhibitory effects on cyclin E- and cyclin A-CDK2 complexes. CDKN1B Protein, Human (His) is the recombinant human-derived CDKN1B protein, expressed by E. coli , with N-6*His labeled tag. The total length of CDKN1B Protein, Human (His) is 198 a.a., with molecular weight of ~30.0 kDa.
CDKN1A; CAP20; CDKN1; CIP1; MDA6; PIC1; SDI1; WAF1; Cyclin-dependent kinaseinhibitor 1; CDK-interacting Protein 1; Melanoma differentiation-associated Protein 6; MDA-6; p21
WB, ICC/IF
Human, Mouse, Rat
p21 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 18 kDa, targeting to p21. It can be used for WB,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.
CDKN1A; CAP20; CDKN1; CIP1; MDA6; PIC1; SDI1; WAF1; Cyclin-dependent kinaseinhibitor 1; CDK-interacting Protein 1; Melanoma differentiation-associated Protein 6; MDA-6; p21
WB
Human, Mouse
p21 Antibody (YA254) is a non-conjugated and Rabbit origined monoclonal antibody about 18 kDa, targeting to p21. It can be used for WB assays with tag free, in the background of Human, Mouse.
